Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA

Reuters Staff  |  February 5, 2020

NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm.

“Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology. “The findings support that systematic use of ultrasound does not provide a benefit in the follow-up of patients with early RA.”1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The goal of RA care today is to treat patients to clinical remission, but these patients may still have subclinical inflammation visible on ultrasound or magnetic resonance imaging, Dr. Sundin and his team note. Two trials of structured ultrasound assessment in patients with early RA did not show a benefit of targeting imaging remission instead of clinical remission, they add, although there was a trend toward the ultrasound groups in both studies showing less radiographic erosive damage.

In the current study, the authors analyzed data from one of these trials, the ARCTIC trial, on 218 participants who had magnetic resonance imaging (MRI) scans at baseline and at least one follow-up MRI.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There were no differences between the ultrasound group and the conventional treat-to-target group in bone marrow edema, synovitis or tenosynovitis based on MRI, which improved for the first year of the study with sustained benefit over the second year. The risk of progression to erosions on MRI was also similar for both groups, at 39% with ultrasound and 33% without ultrasound (P=0.40).

“The MRI results, with no trend towards less joint damage progression in the ultrasound arm, support the conclusions of the primary outcomes of the above mentioned trials—that an ultrasound-guided strategy does not lead to improved treatment outcomes,” Dr. Sundin and colleagues write.

“Our findings support the current treatment recommendations for early RA,” they conclude.


Reference

  1. Sundin U, Aga AB, Skare Ø, et al. Conventional versus ultrasound treat to target: No difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. Rheumatology (Oxford). 2020 Jan 30. pii: kez674. [Epub ahead of print]

Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:imagingMagnetic resonance imaging (MRI)MRIRheumatoid Arthritis (RA)Treat-to-TargetUltrasound

Related Articles

    Imaging in Ankylosing Spondylitis

    April 1, 2015

    MRI inflammation, fat and new bone formation in the sacroiliac joints, spine in patients with AS

    Envision Arthritis Pathology

    April 1, 2008

    MRI advances in RA and OA

    Musculoskeletal Ultrasound: A Valuable Tool for Diagnosing Rheumatic Illnesses

    Musculoskeletal Ultrasound: A Valuable Tool for Diagnosing Rheumatic Illnesses

    October 15, 2015

    Musculoskeletal (MSK) ultrasound is a valuable imaging modality for the practicing rheumatologist and provides an efficient tool with high diagnostic value in the evaluation of patients with musculoskeletal complaints. The use of MSK ultrasound has evolved in the U.S. due to the emergence of less-expensive, portable ultrasound units, which provide high-quality gray-scale and power Doppler…

    Ultrasound as RA Treat-to-Target Strategy Doesn’t Improve Long-Term Outcomes

    December 18, 2018

    An analysis of treat-to-target therapy assessing two ultrasound definitions of remission for patients with early rheumatoid arthritis (RA) has concluded that using ultrasound remission as a target was not associated with better long-term outcomes for RA patients.1 Compared with MRI, ultrasound costs less, is more accessible and offers the ability to scan more joints in…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences